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Objectives: Transrenal fixation (TFX) of aortic endografts is thought to increase the risk for renal infarction and impaired
renal function. We studied the late effects of TFX on renal function and perfusion.
Methods: Of 189 patients with commercial aortic endografts, which we inserted between 1995 and 2002, we reviewed data
for 130 patients (112 men, 18 women) with available creatinine (Cr) concentration and contrast enhanced computed
tomography (CT) scans preoperatively and 1 to 97 months after the procedure. Of the 130 patients, 69 patients had TFX
and 61 patients had infrarenal fixation (IFX). Both groups were physiologically comparable. Average age was 76 8 years
for patients with TFX and 75  8 years for patients with IFX. Presence of renal infarct or renal artery occlusion was
determined by nephrograms on serial contrast-enhanced CT scans.
Results: Mean follow-up was 17  16 months (range, 1-54 months) for TFX and 21  21 months (range, 1-97 months)
for IFX. Mean serum Cr concentration increased significantly during long-term follow-up in both groups (TFX, 1.3 
0.5 mg/dL to 1.5  0.8 mg/dL, P < .01; IFX, 1.3  0.7 mg/dL to 1.4  0.8 mg/dL, P < .03). Creatinine clearance
(CrCl) similarly decreased over long-term follow-up in both groups (TFX, 53.3 17.7 mL/min/1.73 m2 to 47.9 16.2
mL/min/1.73 m2, P < .01; IFX, 58.1 22.7 mL/min/1.73 m2 to 53.1 23.4 mL/min/1.73 m2, P < .02). There were
no significant differences in the increase in Cr concentration (P  .19) or decrease in CrCl (P  .68) between TFX and
IFX groups. Small renal infarcts were noted in four patients (5.8%) in the TFX group and one patient (1.6%) in the IFX
group. No increase in Cr concentration or decrease in CrCl was noted in any patient with a renal infarct. Postoperative
renal dysfunction developed in 7 of 69 patients (10.1%) in the TFX group and 7 of 61 patients (11.5%) in the IFX group.
There were no statistically significant differences between groups with respect to number of patients with new renal
infarcts (P  .37) or postoperative renal dysfunction (P  .81).
Conclusion: There is a slight increase in serum Cr concentration and decrease in CrCl after aortic endografting. However,
there was no significant difference in these changes between patients with TFX and IFX. Although TFX may produce a
higher incidence of small renal infarcts, these do not impair renal function. Thus our midterm results suggest that TFX
can be performed safely, with no greater change in renal function than observed after IFX. (J Vasc Surg 2003;38:
639-44.)
Secure fixation of endovascular grafts (EVGs) within
the normal proximal infrarenal neck in patients undergoing
endovascular aortoiliac aneurysm repair (EVAR) is of crit-
ical importance to prevent development of a type I en-
doleak or EVG migration. Early surgeon-made EVGs in-
corporated a large balloon-expandable stent with an
uncovered portion that could be placed across the renal
arteries when the proximal neck was short. Recently there
has been a proliferation of commercial endografts available
for clinical trials and increasingly on the open market.
These grafts can be classified as those that use transrenal
fixation (TFX), in which all or a portion of bare stent crosses
the renal arteries, and those that use infrarenal fixation
(IFX), in which no bare stent crosses the renal arteries.
After EVAR, the infrarenal neck dilates over time,1-6
and there are reports of proximal EVG migration.7,8 The
purported advantage of TFX is that it may enable treatment
of aneurysms with short or flared proximal necks by provid-
ing more durable fixation in the suprarenal aorta. This
portion of the aorta is less susceptible to aneurysm dis-
ease.1,9,10 Purported disadvantages of TFX are possible
impairment of renal function due to renal infarct, and
difficulty in removal if conversion to open repair is required.
We reviewed our experience with commercial en-
dografts that use both TFX and IFX, and analyzed late
effects on renal function and perfusion.
METHODS
Prospectively collected data for all patients undergoing
EVAR at a single institution between 1995 and 2002 were
reviewed. Two hundred eighty-nine endografts were
placed for treatment of abdominal aortic aneurysms (AAAs)
during this period. One hundred of the 289 patients re-
ceived homemade endovascular devices, and were excluded
from the study because the device is not readily available
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and is not widely used. In addition, patients with the
homemade devices were uniformly at high risk, because of
both anatomy and physiology. The remaining 189 patients
received commercial endograft devices. Creatinine (Cr)
concentration and contrast enhanced computed tomogra-
phy (CT) scans were available for review for 130 of these
189 patients, both preoperatively and at least 1 month
postprocedure. The other 59 patients with commercial
devices were excluded because either follow-up was too
short, or Cr concentration or CT scans were not available
for both periods. Cr concentration obtained at three differ-
ent intervals (preprocedure, 1 to 7 days post-procedure,
and longer than 1 month postprocedure) and contrast CT
scans obtained at two different intervals (pre-procedure and
longer than 1 month postprocedure) were reviewed. CT
scans were obtained with a HiSpeed Advantage scanner
(General Electric Medical Systems, Milwaukee, Wis). Intra-
venous contrast medium (Omnipaque 300; Sanofi-
Winthrop, New York, NY) was administered as a single
uniphasic power injection at a rate of 3 to 4 mL/s to a total
of 120 to 150 mL. A 30-second breath hold was used for
abdominal scan acquisition. Scans were obtained from 1 cm
above the celiac artery down to the femoral arteries. Colli-
mation of 3 mm and pitch of 2 were used to cover the entire
anatomic region. Images were reconstructed at 1.5-mm
intervals, per our institutional protocol. No oral contrast
medium was used. Patients were allocated to the TFX
group if any portion of bare stent was seen cephalad to the
inferior border of either renal artery on postoperative CT
scans or on an intraoperative angiogram. Otherwise, they
were allocated to the IFX group, regardless of graft design.
Normal preoperative Cr concentration was defined as
1.5 mg/dL or less. Normal Cr concentration ranges from
0.5 to 1.5 mg/dL at our institution. Postoperative renal
dysfunction was defined as increase in Cr concentration
greater than 0.5 mg/dL above baseline. Cr clearance
(CrCl) was estimated with the formula of Cockcraft and
Gault, that is, CrCl ([140  age]  weight)/(plasma Cr
 72), to account at least in part for age-related differences
in serum Cr. This result was multiplied by 0.85 as a correc-
tion factor in female patients. The presence of a renal infarct
or renal artery occlusion was determined by nephrograms
on serial CT scans. Small renal infarcts were defined as
occupying less than 20% of total kidney volume, and large
renal infarcts as occupying more than 20% of kidney vol-
ume. New renal artery occlusion was defined as complete
absence of flow in a renal artery that had demonstrated flow
on the preoperative CT scan. Operative reports and post-
implant angiograms were also reviewed for evidence of
renal artery perfusion defect or occlusion occurring during
graft placement.
Patient charts were reviewed, and each patient’s age,
comorbid conditions, and presence of new-onset dialysis
were recorded.
Statistical analysis. Continuous variables were com-
pared with the Student t test, and univariate analysis of
categorical variables was performed with the Fisher exact
test or 2 with Yates correction, as indicated (2 for con-
tingency tables, two-tailed P value). Dependent variables
were those related to final outcome of the patient. Differ-
ences were considered significant at P  .05. Stratified
analyses were used as necessary.
RESULTS
Of 130 study patients, 112 were men (86%) and 18
were women (14%). Sixty-nine patients (53%) had TFX
(Talent, World Medical Manufacturing Corp, Sunrise, Fla,
Medtronic/ AVE, Santa Rosa, Calif [n  26]; Zenith,
Cook Inc, Indianapolis, Ind [n  33]; Vanguard, Boston
Scientific/Meadox, Natick, Mass [n 10]) and 61 patients
(47%) had IFX (AneuRx, Medronic/AVE, [n  27]; An-
cure, Guidant Corp, Menlo Park, Calif [n 12]; Excluder,
W. L. Gore & Associates, Flagstaff, Ariz [n 12]; Talent [n
 5]; Vanguard [n  5]). Mean age and mean AAA
diameter at implantation in patients with TFX were 76 8
years and 5.7 0.6 cm, respectively, and 75 8 years and
6.3 1.3 cm in patients with IFX. Mean operative contrast
volume was similar between groups: 157  62 mL (range,
60-325 mL) for TFX, and 154  65 mL (range, 45-380
mL) for IFX. Comorbid conditions were also similar be-
tween the two groups (Table I).
Mean follow-up for patients with both Cr concentra-
tion and contrast-enhanced CT scans available was 17 16
months (range, 1-54 months) for TFX and 21  21
months (range, 1-97 months) for IFX. In the immediate
postoperative period, mean serum Cr concentration did
not change significantly in either the TFX group (1.3 0.5
mg/dL to 1.3 0.6 mg/dL) or the IFX group (1.3 0.7
mg/dL to 1.2  0.9 mg/dL). Mean serum Cr concentra-
tion did, however, significantly increase over longer fol-
low-up in both groups (1.5  0.8 mg/dL for TFX, P 
.01; and 1.4  0.8 mg/dL for IFX, P  .03). CrCl was
similarly unchanged in the immediate postoperative period
(53.3 17.7 mL/min/1.73 m2 to 55.1 17.3 mL/min/
1.73 m2 for TFX, and 58.1  22.7 mL/min/1.73 m2 to
60.7  25.1 mL/min/1.73 m2 for IFX), but was signifi-





Pn % n %
Diabetes 9 13 5 8 .54
Coronary artery disease* 47 68 39 64 .75
COPD
†
14 20 14 23 .88
Hypertension
‡
46 66 43 70 .78
Renal insufficiency
§
13 19 9 15 .70
TFX, Transrenal fixation; IFX, infrarenal fixation; COPD, chronic obstruc-
tive pulmonary disease; FEV, forced expiratory volume in 1 s; FVC, forced
vital capacity.
*History of myocardial infarction, angina, or electrocardiographic evidence
of myocardial ischemia.
†
FEV1 1 L or FEV1/FVC 75.‡
History of hypertension; patient taking at least one antihypertensive med-
ication.
§
Preoperative creatinine concentration 	 1.5 mg/dL.
JOURNAL OF VASCULAR SURGERY
October 2003640 Cayne et al
cantly decreased in longer follow-up (47.9  16.2 mL/
min/1.73 m2 for TFX, P .01; and 53.1 P 23.4 mL/min/
1.73 m2 for IFX, P  .02). There were no significant
differences in Cr concentration increase (P  .19) or CrCl
decrease (P  .68) between the TFX and IFX groups
(Table II).
Small renal infarcts were noted in four patients (5.8%)
in the TFX group (Zenith, unilateral, n  2; Talent, bilat-
eral n  1; Vanguard, unilateral, n  1) and one patient
(1.6%) in the IFX group (AneuRx, unilateral). All infarcts
were demonstrated on the first postoperative CT scan,
obtained within 1 month postprocedure. Small, unilateral
accessory renal arteries were intentionally covered in two of
the four patients (50%), one with unilateral and one with
bilateral renal infarcts (Figure, A-D), in the TFX group, but
not in the one patient (0%) in the IFX group. The patient in
the IFX group with a postoperative renal infarct underwent
intraoperative renal stent placement when the covered por-
tion of the EVG partially occluded a main renal artery on
the affected side. There was no statistically significant dif-
ference between groups with respect to number of infarcts
(P  .21) or number of patients with renal infarcts (P 
.37). None of the patients with a new renal infarct exhibited
increased Cr concentration or decreased CrCl. No large
infarcts or new renal artery occlusions were noted in either
group.
Postoperative renal dysfunction developed in 7 of 69
patients (10.1%) in the TFX group and 7 of 61 patients
(11.5%) in the IFX group. Incidence of postoperative renal
dysfunction in the subgroup of patients with normal pre-
operative renal function was 4 of 56 (7.1%) for those with
TFX and 5 of 52 (9.6%) for those with IFX. For the
subgroup of patients with elevated preoperative Cr concen-
tration, increased renal dysfunction developed in 3 of 13
(23%) in the TFX group and 2 of 9 (22.2%) in the IFX
group. There were no statistically significant differences
between groups with respect to postoperative renal dys-
function (Table III). Four patients with postoperative renal
dysfunction, two from the IFX group (3.3%) and two from
the TFX group (2.9%), subsequently required hemodialy-
sis. The difference between groups with respect to new-
onset dialysis was not statistically significant (P  .91)
DISCUSSION
The incidence of post-procedural renal dysfunction
after EVAR in patients with normal preoperative renal
function is approximately 6%.11 We report an overall rate of
post-procedural renal dysfunction of 10.8% (10.1% for
TFX, 11.5% for IFX). The incidence of renal dysfunction in
the subgroup of patients with normal preoperative renal
function in our series was 8.3%, and was similar between
groups (7.1% for TFX, 9.6% for IFX). For the subgroup of
patients with elevated preoperative Cr concentration, inci-
dence of renal dysfunction was higher, at 22.7%, but also
was similar between groups (23.1% for TFX, 22.2% for
IFX). This higher incidence of renal dysfunction in patients
with elevated preoperative Cr concentration is consistent
with data from previous studies of contrast-related ne-
phropathy.12,13 Of the patients in our series in whom renal
dysfunction developed, four patients subsequently required
hemodialysis. Two patients (2.9%) were in the TFX group
and two patients (3.3%) were in the IFX group. Therefore
overall risk for postprocedural renal dysfunction or new-
onset dialysis was no greater for patients with TFX than for
those with IFX.
Placing uncovered stents across non–visceral arterial
branch orifices has proved benign in studies in both ani-
mals14 and human beings15,16. However, controversy re-
mains concerning the consequences of placing a bare stent
across the renal arteries. Experimental data in pigs suggests
that bare stents placed across the renal arteries may com-
promise renal perfusion, as a result of neointimal ingrowth
between stent struts, as early as 4 weeks.17 Raithel and
Kraus18 reported an increased renal infarction rate of 23%,
versus 6.6%, when EVG devices with TFX were compared
with those with IFX for treatment of AAAs.18 We have not
observed such a high infarction rate associated with EVG
devices that use TFX. In addition, we did not find a
statistically significant difference in the number of patients
with renal infarcts between the IFX and TFX groups.
Table II. Changes in renal function
TFX (n  69) IFX (n  61)
Preoperative
Postoperative








Creatinine (mg/dL) 1.3  0.5 1.3  0.6 1.5  0.8 .01 1.3  0.7 1.2  0.9 1.4  0.8 .03
Creatinine clearance
(mL/min/1.73 m2)
53.3  17.7 55.1  17.3 47.9  16.2 .01 58.1  22.7 60.7  25.4 53.1  23.4 .02
Patients with new small renal infarcts — — 4 (5.8%)
‡
— — 1 (1.6%)
‡
Patients with new large renal infarcts — — 0 — — 0
Patients with new renal artery occlusions — 0 0 — 0 0
Patients with new onset dialysis (any cause) — 0 2 (2.9 %) — 0 2 (3.3%)
*Mean, 17  16 months.
†
Mean, 21  21 months.
†
Statistical significance of late postoperative change in creatinine concentration or creatinine clearance, compared with preoperative value.
‡
Increased creatinine concentration not noted.
JOURNAL OF VASCULAR SURGERY
Volume 38, Number 4 Cayne et al 641
Renal infarcts may be related to embolization during
EVG placement or to coverage of an accessory renal
artery. Such embolic events have been noted in the
hypogastric arteries.19 All of our infarcts were noted on
the first postoperative CT scan, and therefore occurred
during the procedure or soon thereafter. None of these
patients had thrombus in the infrarenal neck, and none
had renal artery stenosis. Of the six renal infarcts in five
patients, two infarcts were accounted for by an inten-
tionally covered accessory renal artery. One infarct may
have been accounted for by an infrarenal graft that
inadvertently covered a portion of the main renal artery
orifice on the affected side. The exact cause of the other
three infarcts is not clear, and may or may not be related
to the transrenal bare stent. Regardless of the cause, in
the present study, as in previous studies,11,20,21 the small
A, Intraoperative angiogram shows patent lower right accessory renal artery before transrenal endograft deployment. B, Postdeployment
angiogram demonstrates absence of flow in lower right accessory renal artery. C, Preoperative CT scan shows normal contrast-enhanced
nephrograms. D, Postoperative CT scan demonstrates bilateral small renal infarcts.
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number of renal infarctions that occurred were clinically
benign.
Other studies support the safety of placing a portion of
bare stent across the renal arteries. In Parodi’s22 series of 50
patients reported in 1995, 6 patients had TFX. None of
these patients demonstrated a resultant change in renal
blood flow or development of renal failure. More recently
Burks et al23 found no stenoses, thromboembolisms, or
occlusions in the renal, superior mesenteric, or celiac
branch vessels in 95 patients undergoing EVAR with trans–
visceral artery fixation. Excluding two patients with inad-
vertent coverage of the renal arteries with the fabric-
covered portion of the endograft, these authors found no
significant increase in Cr concentration over an average of
25 months of follow-up. Bove et al24 observed 28 patients
with TFX over 12 months, with CT scans and duplex
ultrasound scans. They found no evidence of infarct, and
only two patients exhibited moderate narrowing of the
renal artery to greater than 60% stenosis. One of 19 patients
in this series, with normal preoperative renal function, did
have persistently elevated Cr concentration postopera-
tively. Kramer et al20 reviewed 193 renal arteries in 99
patients with aortic endografts. Sixty-nine renal ostia had
TFX, and 124 ostia had no stent coverage. Renal infarcts
were not statistically different between groups, and were
found in 8.7% of those with TFX and 5.6% of those with
IFX. Only one patient with a renal infarct had an elevated
Cr concentration postoperatively. Greenberg et al,25 in a
midterm update of a multicenter trial of the Zenith stent
graft, reported no renal complications related to TFX in
528 patients and no significant change in Cr concentration
at 18 months of follow-up.
No patients in our series had preoperative high-grade
renal artery stenosis. It is unclear whether placement of
EVGs with TFX in these patients would be more deleteri-
ous, especially in those with ostial renal lesions. Therefore,
given our current data, we are unable to comment on the
safety of TFX in patients with preoperative high-grade renal
artery stenosis.
One limitation of our study is that we were unable to
accurately report on postoperative changes in blood pres-
sure (renovascular hypertension) that might have resulted
from transrenal stenting. Two small series in the literature,
of 18 and 37 patients, reported no significant changes in
average recorded blood pressure at 6 and 12 months after
TFX.26,27 Longer follow-up data will have to be studied.
It is worth noting that, although the Cockcraft and
Gault formula compensates for Cr concentration changes
related to weight, gender, and age, it overestimates glomer-
ular filtration rate by 16%.28 However, given our available
data, we believe this equation resulted in the best possible
estimation of CrCl.
In conclusion, after EVAR renal function declines
slightly with both IFX and TFX. Our data show no overall
difference between patients with TFX and IFX with respect
to infarcts, decline in renal function, or onset of dialysis.
There were a slightly greater number of renal infarcts in the
TFX group, but these infarcts were clinically inconsequen-
tial. Thus our midterm results suggest that TFX can be
performed safely, without greater compromise in renal
function than observed after IFX, and may provide advan-
tages of long-term stability of EVAR.
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